November 18, 2016 - By Nellie Frank · 0 Comments
MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS) institutional sentiment decreased to 1.08 in 2016 Q2. Its down -0.09, from 1.17 in 2016Q1. The ratio fall, as 14 hedge funds opened new or increased equity positions, while 12 decreased and sold positions in MARINUS PHARMACEUTICALS INC. The hedge funds in our partner’s database now own: 6.42 million shares, down from 7.28 million shares in 2016Q1. Also, the number of hedge funds holding MARINUS PHARMACEUTICALS INC in their top 10 equity positions decreased from 2 to 0 for a decrease of 2. Sold All: 7 Reduced: 5 Increased: 9 New Position: 5.
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $20.11 million. The Firm focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It currently has negative earnings. The Company’s clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
About 372,533 shares traded hands. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 83.31% since April 18, 2016 and is downtrending. It has underperformed by 87.74% the S&P500.
According to Zacks Investment Research, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.”
Sphera Funds Management Ltd. holds 0.39% of its portfolio in Marinus Pharmaceuticals Inc for 1.17 million shares. Dafna Capital Management Llc owns 90,237 shares or 0.09% of their US portfolio. Moreover, J. Goldman & Co Lp has 0.04% invested in the company for 547,290 shares. The Colorado-based Arrowpoint Asset Management Llc has invested 0.02% in the stock. Orbimed Advisors Llc, a New York-based fund reported 867,600 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 6 sales for $2.08 million net activity.
Ratings analysis reveals 50% of Marinus Pharmaceuticals’s analysts are positive. Out of 4 Wall Street analysts rating Marinus Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $2.50 while the high is $21. The stock’s average target of $12.50 is 1046.79% above today’s ($1.09) share price. MRNS was included in 9 notes of analysts from August 5, 2015. The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has “Outperform” rating given on Wednesday, August 5 by Oppenheimer. The company was downgraded on Tuesday, June 14 by Oppenheimer. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, December 17. The rating was maintained by Oppenheimer on Friday, October 30 with “Outperform”. Jefferies initiated Marinus Pharmaceuticals Inc (NASDAQ:MRNS) rating on Tuesday, November 17. Jefferies has “Buy” rating and $14 price target. On Tuesday, June 14 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, March 8. Jefferies maintained the stock with “Buy” rating in Tuesday, June 14 report. The stock has “Buy” rating given by Jefferies on Wednesday, August 10.
More news for Marinus Pharmaceuticals Inc (NASDAQ:MRNS) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on May 16, 2014. 247Wallst.com‘s article titled: “Why Marinus Pharmaceuticals Shares Are Sliding” and published on June 13, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank